iTeos Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $125 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
iTeos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).
SEC Form D · Apr 2020
The industry group it chose in its notices: Other Technology.
SEC Form D · Apr 2020
That is all the official record says: iTeos Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Boxer Asset Management Inc. | Fund or asset manager | not stated | not stated | Held Series B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Boxer Capital, LLC | Fund or asset manager | not stated | not stated | Held Series B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management Investors BV2014 LLC | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management Investors BV2018 LLC | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioimpact LLC | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 (B), L.P. | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 GP LLC | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014 LLC | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2014, L.P. | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioventures 2018 (B), L.P. | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2018 GP LLC | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2018 LLC | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioventures 2018, L.P. | Venture capital | not stated | not stated | Held Series B and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Oncology Impact Management GP LLC | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock (Form 3, 2020) | SEC Form 3 |
| MVA Investors, LLC | Fund or asset manager | not stated | not stated | Held Series B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Oncology Impact Fund (Cayman) Management L.P. | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| UBS Oncology Impact Fund L.P. | Fund or asset manager | not stated | not stated | Held Series B and B-2 preferred stock (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 36 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Michel Detheux | Executive officer | Apr 2020 |
| Ansbert Gadicke | Director | Apr 2020 |
| CHris Buyse | Director | Apr 2020 |
| David Hallal | Director | Apr 2020 |
| Detlev Biniszkiewicz | Director | Apr 2020 |
| Jonathan Skipper | Director | Apr 2020 |
| Michel Detheux | Director | Apr 2020 |
| Priyanka Belawat | Director | Apr 2020 |
| Tim Van Hauwermeiren | Director | Apr 2020 |